Project Details
Description
A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastic Non-Small Cell Lung Cancer and Tumors with High Expression of PD-LI ≥ 50%
| Status | Finished |
|---|---|
| Effective start/end date | 5/1/18 → 12/10/18 |
Funding
- ARMO BIOSCIENCES, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.